Sinovac Life Sciences Co., Ltd.

This study tests a new vaccine (PCV24) that protects against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. It involves 180 healthy children aged 2 to 23 months. The goal is to see if the vaccine is safe and triggers a strong …

This study tests a new 13-valent pneumococcal vaccine (PCV13) in 3,080 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine is safe and triggers a strong immune response against pneumococcal bacteria, which can cause pneumonia, meningitis, and e…

This study tests a new vaccine (PCV24) that protects against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. About 420 healthy children aged 2 months to 5 years will receive either the new vaccine or an existing one to compare …